ImmunoGen announced that Susan Altschuller, Ph.D. has been appointed as the company’s Senior Vice President and Chief Financial Officer.

“Susan is an outstanding addition to our management team and we are pleased to welcome her at this pivotal moment for ImmunoGen, with the registration studies for our lead program enrolling, our earlier-stage portfolio advancing, and a strong balance sheet,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.

“Her energy and extensive experience in investor relations, business planning, and corporate finance will be invaluable as we enter the next stage of ImmunoGen’s evolution and look to allocate our capital in the most effective and efficient manner possible,” Enyedy added.

“I am excited to be joining the ImmunoGen team and look forward to playing a key role in the meaningful work the Company does to deliver more good days for people living with cancer,” said Altschuller said.

Advertisement #2
 

“The prospects and potential of its novel portfolio of next-generation antibody-drug conjugates is exciting, particularly as the organization transitions from clinical-stage to fully-integrated commercial biotech,” she further noted.

Susan Altschuller, Ph.D
Susan Altschuller, Ph.D., has been appointed as the ImmunoGen’s Senior Vice President and Chief Financial Officer. Photo Courtesy: © 2020 LinkedIn/Susan Altschuller.

Experience
Altschuller has 20 years of financial management, investor relations, and business planning experience with leading pharmaceutical and biotechnology companies. She joins ImmunoGen from Alexion Pharmaceuticals where she started as Head of Investor Relations before moving to Head of Enterprise Finance, where she led global financial reporting and provided counsel on investment prioritization to support the Company’s strategic imperatives.

Prior to joining Alexion, Altschuller was Head of Investor Relations at Bioverativ, since 2018 a division of Sanofi Genzyme specializing in the discovery, development, and delivery of therapies for the treatment of hemophilia, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen spin-off.

Early in her career, Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. She received a BSE in Biomedical Engineering with Honors from Tulane University, a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management.